Multiple Myeloma Clinical Trial
MMRF Molecular Profiling Protocol
Summary
Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.
Full Description
Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.
Eligibility Criteria
Inclusion Criteria:
Patients must have a diagnosis of multiple myeloma or related malignancy
Patients are undergoing standard of care bone marrow aspirates
Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration.
Procedure-specific signed informed consent form prior to initiation of any study-related procedures.
Exclusion Criteria:
It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate.
Patients who are incarcerated are not eligible to participate.
Women who are pregnant
Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Scottsdale Arizona, 85259, United States
Duarte California, 91010, United States
San Francisco California, 94143, United States
Jacksonville Florida, 32224, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, , United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02215, United States
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States
Rochester Minnesota, 55905, United States
Saint Louis Missouri, 63110, United States
Hackensack New Jersey, 07601, United States
New York New York, 10029, United States
Charlotte North Carolina, 28204, United States
Columbus Ohio, 43210, United States
Nashville Tennessee, 37203, United States
Dallas Texas, 75246, United States
Fairfax Virginia, , United States
Toronto Ontario, M5G 2, Canada
How clear is this clinincal trial information?